HRP20200932T1 - Sisavačke stanice koje eksprimiraju antigene citomegalovirusa - Google Patents
Sisavačke stanice koje eksprimiraju antigene citomegalovirusa Download PDFInfo
- Publication number
- HRP20200932T1 HRP20200932T1 HRP20200932TT HRP20200932T HRP20200932T1 HR P20200932 T1 HRP20200932 T1 HR P20200932T1 HR P20200932T T HRP20200932T T HR P20200932TT HR P20200932 T HRP20200932 T HR P20200932T HR P20200932 T1 HRP20200932 T1 HR P20200932T1
- Authority
- HR
- Croatia
- Prior art keywords
- complex
- cho cell
- cho
- pentameric complex
- pul130
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title claims 6
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004962 mammalian cell Anatomy 0.000 title 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 101001090901 Homo sapiens Retroelement silencing factor 1 Proteins 0.000 claims 3
- 101000864837 Homo sapiens SIN3-HDAC complex-associated factor Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 108010091175 Matriptase Proteins 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102100034981 Retroelement silencing factor 1 Human genes 0.000 claims 1
- 102100030066 SIN3-HDAC complex-associated factor Human genes 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Rekombinantna stanica CHO, naznačena time što sadrži:
jedan ili više polinukleotidnih sljedova koji kodiraju citomegalovirusni (CMV) pentamerni kompleks, gdje navedeni pentamerni kompleks sadrži: gH ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, gL ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, pUL128 ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, pUL130 ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, te pUL131 ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131;
gdje su navedeni jedan ili više polinukleotidnih sljedova integrirani genomsku DNA navedene stanice CHO; i
gdje je razina eksprimiranja ili aktivnost proteina C12orf35 smanjena u navedenoj stanici CHO, u usporedbi s divljim tipom stanice.
2. Stanica CHO u skladu s patentnim zahtjevom 1, naznačena time što je navedena stanica CHO stanica CHO-K1, CHO-DUXB11, CHO-DG44 stanica ili stanica CHO-S.
3. Stanica CHO u skladu s patentnim zahtjevom 2, naznačena time što je deletirana najmanje jedna kopija genomskog slijeda gena C12orf35, ili je deletirano najmanje 50% kodirajućeg slijeda navedenog gena C12orf35.
4. Stanica CHO u skladu s patentnim zahtjevom 3, naznačena time što navedeni deletirani slijed sadrži dio telomernog područja kromosoma 8 stanice CHO.
5. Stanica CHO u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačena time što je smanjena razina eksprimiranja ili aktivnost proteina FAM60A u navedenoj stanici, u usporedbi s divljim tipom stanice.
6. Stanica CHO u skladu s patentnim zahtjevom 5, naznačena time što je deletirana najmanje jedna kopija genomskog slijeda gena FAM60A, ili je deletirano najmanje 50% kodirajućeg slijeda navedenog gena FAM60A.
7. Stanica CHO u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što je smanjena razina eksprimiranja ili aktivnost matriptaze u navedenoj stanici, u usporedbi s divljim tipom stanice.
8. Stanica CHO u skladu s patentnim zahtjevom 7, naznačena time što navedena stanica sadrži mutaciju u eksonu 2 matriptaznog gena.
9. Stanica CHO u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačena time što navedeni fragment gH koji tvori kompleks sadrži ektodomenu proteina gH pune duljine.
10. Stanica CHO u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačena time što je navedeni pentamerni kompleks topljiv.
11. Stanica CHO u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačena time što se navedeni pentamerni kompleks izlučuje iz stanice domaćina.
12. Kultura u velikom mjerilu koja sadrži stanicu CHO u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačena time što je navedena kultura velika najmanje 20 litara.
13. Kultura u velikom mjerilu u skladu s patentnim zahtjevom 12, naznačena time što je prinos pentamernog kompleksa iz CMV najmanje 0,05 g/l.
14. Postupak proizvodnje citomegalovirusnog (CMV) pentamernog kompleksa, gdje navedeni pentamerni kompleks sadrži: gH ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, gL ili njegov fragment koji tvori pentamerni kompleks gH/gL/pUL128/pUL130/pUL131, pUL128 ili njegov fragment koji tvori kompleks, pUL130 ili njegov fragment koji tvori kompleks, te pUL131 ili njegov fragment koji tvori kompleks, naznačen time što se sastoji u:
(i) uzgoju stanice CHO u skladu s bilo kojim od patentnih zahtjeva 1-11 u pogodnim uvjetima, pri čemu se eksprimira navedeni pentamerni kompleks; i
(ii) prikupljanju navedenog pentamernog kompleksa iz kulture.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14191385.5A EP3015475A1 (en) | 2014-10-31 | 2014-10-31 | Mammalian cells expressing cytomegalovirus antigens |
| EP15791768.3A EP3212660B1 (en) | 2014-10-31 | 2015-10-29 | Mammalian cells expressing cytomegalovirus antigens |
| PCT/IB2015/058349 WO2016067239A1 (en) | 2014-10-31 | 2015-10-29 | Mammalian cells expressing cytomegalovirus antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200932T1 true HRP20200932T1 (hr) | 2020-09-18 |
Family
ID=51844603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200932TT HRP20200932T1 (hr) | 2014-10-31 | 2020-06-10 | Sisavačke stanice koje eksprimiraju antigene citomegalovirusa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10414802B2 (hr) |
| EP (2) | EP3015475A1 (hr) |
| JP (1) | JP6688297B2 (hr) |
| CN (1) | CN107075486B (hr) |
| AR (1) | AR102464A1 (hr) |
| BE (3) | BE1023364B1 (hr) |
| BR (1) | BR112017008827A2 (hr) |
| CA (1) | CA2964859C (hr) |
| CY (1) | CY1123405T1 (hr) |
| DK (1) | DK3212660T3 (hr) |
| ES (1) | ES2799735T3 (hr) |
| HR (1) | HRP20200932T1 (hr) |
| HU (1) | HUE049356T2 (hr) |
| LT (1) | LT3212660T (hr) |
| MX (1) | MX2017005661A (hr) |
| PL (1) | PL3212660T3 (hr) |
| PT (1) | PT3212660T (hr) |
| SI (1) | SI3212660T1 (hr) |
| WO (1) | WO2016067239A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015103891A (ru) | 2012-07-06 | 2016-08-27 | Новартис Аг | Комплексы белков цитомегаловируса |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| PT3137595T (pt) * | 2014-04-29 | 2019-06-19 | Novartis Ag | Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| CN107723276B (zh) * | 2017-11-02 | 2021-08-13 | 上海交通大学 | 一种稳定高表达目标产物的细胞株的构建方法和试剂盒 |
| CA3099381A1 (en) | 2018-05-04 | 2019-11-07 | SpyBiotech Limited | Vaccine composition |
| JP7179872B2 (ja) * | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN117222415A (zh) * | 2020-12-02 | 2023-12-12 | Seqirus公司 | 多顺反子rna疫苗及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE69032809T2 (de) | 1989-11-06 | 1999-07-08 | Cell Genesys Inc | Herstellung von Proteinen mittels homologer Rekombination |
| US5589392A (en) | 1991-01-14 | 1996-12-31 | Stratagene | Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter |
| US7704510B2 (en) | 2006-06-07 | 2010-04-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| ES2716243T3 (es) * | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
| RU2015103891A (ru) | 2012-07-06 | 2016-08-27 | Новартис Аг | Комплексы белков цитомегаловируса |
| JP6392245B2 (ja) | 2012-12-18 | 2018-09-19 | ノバルティス アーゲー | 遺伝子改変哺乳動物細胞における治療用タンパク質の産生 |
| PL3083677T3 (pl) | 2013-12-20 | 2020-03-31 | Novartis Ag | Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania |
| KR102288857B1 (ko) | 2013-12-20 | 2021-08-11 | 노파르티스 아게 | 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법 |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| PT3137595T (pt) | 2014-04-29 | 2019-06-19 | Novartis Ag | Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse |
-
2014
- 2014-10-31 EP EP14191385.5A patent/EP3015475A1/en not_active Withdrawn
-
2015
- 2015-10-29 WO PCT/IB2015/058349 patent/WO2016067239A1/en active Application Filing
- 2015-10-29 HU HUE15791768A patent/HUE049356T2/hu unknown
- 2015-10-29 DK DK15791768.3T patent/DK3212660T3/da active
- 2015-10-29 CN CN201580059495.8A patent/CN107075486B/zh active Active
- 2015-10-29 LT LTEP15791768.3T patent/LT3212660T/lt unknown
- 2015-10-29 SI SI201531242T patent/SI3212660T1/sl unknown
- 2015-10-29 AR ARP150103502A patent/AR102464A1/es unknown
- 2015-10-29 MX MX2017005661A patent/MX2017005661A/es unknown
- 2015-10-29 BR BR112017008827-4A patent/BR112017008827A2/pt not_active Application Discontinuation
- 2015-10-29 BE BE2015/5701A patent/BE1023364B1/fr not_active IP Right Cessation
- 2015-10-29 US US15/522,455 patent/US10414802B2/en active Active
- 2015-10-29 CA CA2964859A patent/CA2964859C/en active Active
- 2015-10-29 PT PT157917683T patent/PT3212660T/pt unknown
- 2015-10-29 JP JP2017523410A patent/JP6688297B2/ja active Active
- 2015-10-29 ES ES15791768T patent/ES2799735T3/es active Active
- 2015-10-29 PL PL15791768T patent/PL3212660T3/pl unknown
- 2015-10-29 EP EP15791768.3A patent/EP3212660B1/en active Active
-
2016
- 2016-11-24 BE BE2016/5876A patent/BE1023840B1/fr not_active IP Right Cessation
- 2016-11-24 BE BE2016/5877A patent/BE1023841B1/fr not_active IP Right Cessation
-
2020
- 2020-06-10 HR HRP20200932TT patent/HRP20200932T1/hr unknown
- 2020-06-16 CY CY20201100546T patent/CY1123405T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3212660B1 (en) | 2020-03-25 |
| HUE049356T2 (hu) | 2020-09-28 |
| MX2017005661A (es) | 2017-06-26 |
| CN107075486B (zh) | 2021-06-22 |
| WO2016067239A1 (en) | 2016-05-06 |
| BE1023841A1 (fr) | 2017-08-09 |
| ES2799735T3 (es) | 2020-12-21 |
| SI3212660T1 (sl) | 2020-07-31 |
| US10414802B2 (en) | 2019-09-17 |
| CN107075486A (zh) | 2017-08-18 |
| AR102464A1 (es) | 2017-03-01 |
| CY1123405T1 (el) | 2021-12-31 |
| JP2017534283A (ja) | 2017-11-24 |
| PT3212660T (pt) | 2020-06-23 |
| BE1023840A1 (fr) | 2017-08-09 |
| PL3212660T3 (pl) | 2020-10-05 |
| EP3212660A1 (en) | 2017-09-06 |
| LT3212660T (lt) | 2020-07-10 |
| BE1023364A1 (fr) | 2017-02-20 |
| JP6688297B2 (ja) | 2020-04-28 |
| US20170362278A1 (en) | 2017-12-21 |
| EP3015475A1 (en) | 2016-05-04 |
| DK3212660T3 (da) | 2020-06-15 |
| BE1023841B1 (fr) | 2017-08-10 |
| BE1023364B1 (fr) | 2017-02-20 |
| BE1023840B1 (fr) | 2017-08-10 |
| CA2964859C (en) | 2023-04-04 |
| CA2964859A1 (en) | 2016-05-06 |
| BR112017008827A2 (pt) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200932T1 (hr) | Sisavačke stanice koje eksprimiraju antigene citomegalovirusa | |
| CN104745626B (zh) | 一种条件性基因敲除动物模型的快速构建方法及应用 | |
| Daimon et al. | Recent progress in genome engineering techniques in the silkworm, B ombyx mori | |
| JP6916188B2 (ja) | プロトプラストからの全植物体の製造方法 | |
| HRP20201040T1 (hr) | Inženjering složenog genoma omogućen sustavom crispr | |
| CN102597241B (zh) | 用于生产感兴趣的化合物的经改进的宿主细胞 | |
| RU2020134412A (ru) | Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк | |
| AU2013279333C1 (en) | Site-specific integration | |
| JP2018533375A5 (hr) | ||
| JP2015508651A5 (hr) | ||
| NZ596453A (en) | Antibiotic-free plasmid | |
| JP2012095670A5 (hr) | ||
| JP2019505175A5 (hr) | ||
| JP2013507935A5 (hr) | ||
| JP2016514957A5 (hr) | ||
| Goncalves et al. | Concerted nicking of donor and chromosomal acceptor DNA promotes homology-directed gene targeting in human cells | |
| Chang et al. | Scaffold/matrix attachment regions from CHO cell chromosome enhanced the stable transfection efficiency and the expression of transgene in CHO cells | |
| RU2017121232A (ru) | Плазмиды и способ получения вирусных частиц | |
| JP2013516982A5 (hr) | ||
| RU2013104989A (ru) | Элемент днк, обладающий активностью, направленной на усиление экспрессии чужеродного гена | |
| RU2015139592A (ru) | Терминаторная последовательность sb-ubi для экспрессии генов в растениях | |
| Watanabe et al. | Gene amplification system based on double rolling-circle replication as a model for oncogene-type amplification | |
| MY152746A (en) | Altering enzyme balance through fermentation conditions | |
| Mitchell et al. | De novo assembly, delivery and expression of a 101 kb human gene in mouse cells | |
| TR201907221T4 (tr) | G-csf üretimine yönelik yöntem. |